Gebski VJ - Search Results

1

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.

Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. Lee CK, et al. Among authors: gebski vj. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42. doi: 10.1093/jnci/djr282. Epub 2011 Aug 11. J Natl Cancer Inst. 2011. PMID: 21840849

2

Dynamic balanced randomization for clinical trials.

Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ, Callaghan T. Signorini DF, et al. Among authors: gebski vj. Stat Med. 1993 Dec 30;12(24):2343-50. doi: 10.1002/sim.4780122410. Stat Med. 1993. PMID: 8134737

3

Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.

Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J. Byrne MJ, et al. J Clin Oncol. 1997 Sep;15(9):3141-8. doi: 10.1200/JCO.1997.15.9.3141. J Clin Oncol. 1997. PMID: 9294477 Clinical Trial.

4

Practical approaches to minimize problems with missing quality of life data.

Simes RJ, Greatorex V, Gebski VJ. Simes RJ, et al. Among authors: gebski vj. Stat Med. 1998 Mar 15-Apr 15;17(5-7):725-37. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<725::aid-sim817>3.0.co;2-1. Stat Med. 1998. PMID: 9549819 Review.

5

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ. Toner GC, et al. Among authors: gebski vj. Lancet. 2001 Mar 10;357(9258):739-45. doi: 10.1016/s0140-6736(00)04165-9. Lancet. 2001. PMID: 11253966 Clinical Trial.

6

Combining components of quality of life to increase precision and evaluate trade-offs.

Lumley T, Simes RJ, Gebski V, Hudson HM. Lumley T, et al. Stat Med. 2001 Nov 15;20(21):3231-49. doi: 10.1002/sim.1035. Stat Med. 2001. PMID: 11746315

7

Subgroup analysis: application to individual patient decisions.

Simes RJ, Gebski VJ, Keech AC. Simes RJ, et al. Among authors: gebski vj. Med J Aust. 2004 May 3;180(9):467-9. doi: 10.5694/j.1326-5377.2004.tb06027.x. Med J Aust. 2004. PMID: 15115428 No abstract available.

8

Multiple analyses in clinical trials: sound science or data dredging?

Lord SJ, Gebski VJ, Keech AC. Lord SJ, et al. Among authors: gebski vj. Med J Aust. 2004 Oct 18;181(8):452-4. doi: 10.5694/j.1326-5377.2004.tb06376.x. Med J Aust. 2004. PMID: 15487966 Review. No abstract available.

9

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Burmeister BH, et al. Lancet Oncol. 2005 Sep;6(9):659-68. doi: 10.1016/S1470-2045(05)70288-6. Lancet Oncol. 2005. PMID: 16129366 Clinical Trial.

10

Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective.

Gebski V, Lagleva M, Keech A, Simes J, Langlands AO. Gebski V, et al. J Natl Cancer Inst. 2006 Jan 4;98(1):26-38. doi: 10.1093/jnci/djj002. J Natl Cancer Inst. 2006. PMID: 16391369

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page